Anavex Life Sciences Corp. (AVXL) Holdings Cut by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 0.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 111,249 shares of the biotechnology company’s stock after selling 631 shares during the period. Bank of New York Mellon Corp owned about 0.27% of Anavex Life Sciences Corp. worth $593,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in Anavex Life Sciences Corp. in the 1st quarter worth about $105,000. Northwest Investment Counselors LLC bought a new stake in Anavex Life Sciences Corp. in the 2nd quarter worth about $106,000. American International Group Inc. grew its position in Anavex Life Sciences Corp. by 7.1% in the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 1,329 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in Anavex Life Sciences Corp. in the 2nd quarter worth about $151,000. Finally, Rhumbline Advisers grew its position in Anavex Life Sciences Corp. by 14.8% in the 2nd quarter. Rhumbline Advisers now owns 40,342 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 5,205 shares in the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Anavex Life Sciences Corp. (AVXL) Holdings Cut by Bank of New York Mellon Corp” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/10/30/anavex-life-sciences-corp-avxl-holdings-cut-by-bank-of-new-york-mellon-corp.html.

AVXL has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Monday, August 28th. Maxim Group set a $15.00 price objective on shares of Anavex Life Sciences Corp. and gave the stock a “buy” rating in a research report on Monday, August 7th. Noble Financial reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research report on Friday, September 29th. Finally, ValuEngine downgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, September 28th.

Shares of Anavex Life Sciences Corp. (AVXL) opened at 4.18 on Monday. The firm has a 50-day moving average of $4.33 and a 200-day moving average of $4.33. Anavex Life Sciences Corp. has a 12 month low of $2.76 and a 12 month high of $6.64. The company’s market capitalization is $176.28 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). On average, equities analysts predict that Anavex Life Sciences Corp. will post ($0.37) earnings per share for the current year.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL).

Institutional Ownership by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

What are top analysts saying about Anavex Life Sciences Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anavex Life Sciences Corp. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit